Forskolin

Catalog No.S2449 Synonyms: Coleonol

Forskolin Chemical Structure

Molecular Weight(MW): 410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 270 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 34 Publications

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Description Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
Targets
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
In vitro

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 NXzPNmxNTnWwY4Tpc44hSXO|YYm= MnG3NVAh|ryP MlT3OkBp MlHtbY5kemWjc3XzJJBpd3OyaH;yfYxifGmxbjDv[kBwfmW{ZYjwdoV{e2WmIFvMTGw{KGG2IGO0N|M> M3HXfFI3PDN3NEm4
Mo-DCs Mlm0SpVv[3Srb36gRZN{[Xl? M3;0dlUxKM7:TR?= NEXaTJczPOLCiXi= M1H5WpBzd22xdHXzJGlNNTJ|IIDyc4R2[3Srb36gbY4hfGinIIP1dIVzdmG2YX70JI9nKHq7bX;zZY4he3SrbYXsZZRm\CCPbz3ER5PDqA>? NG[zPZYzPjRzMkm0PC=>
RBMECs  NIHJWHFHfW6ldHnvckBCe3OjeR?= M365dFXDqM7:TR?= NFPsdXoyyqCq NHPCbHhjdG:la4OgeIhmKFKjY{GgbY5i[3SrdnH0bY9vKGmwZIXj[YQh[nliRV3BVE1KUQ>? NIexZYMzPjN3OECzPS=>
INA-6 M2ruVWNmdGxiVnnhZoltcXS7IFHzd4F6 NWXvdI1YOC1zMECg{txO NXTGcpRSPzMkgJno NEnRTGFqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> MYWyOlMxPjZ{NB?=
OPM-2 M1;nc2NmdGxiVnnhZoltcXS7IFHzd4F6 MYOwMVExOCEQvF2= M1HqVFcz6oDLaB?= NHHCbJdqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> M2rY[lI3OzB4NkK0
U266 M17tTGNmdGxiVnnhZoltcXS7IFHzd4F6 MVWwMVExOCEQvF2= NVyyZ4dLPzMkgJno MkexbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NW\rcIp4OjZ|ME[2NlQ>
H929 M2DxPGNmdGxiVnnhZoltcXS7IFHzd4F6 NGL0SYsxNTFyMDFOwG0> M1PnXFcz6oDLaB?= MonnbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NUDKdow6OjZ|ME[2NlQ>
RPMI 8226 NFLheXRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4Dh[|AuOTByIN88US=> MVe3NwKBkWh? M1jKNYlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 M3\iUFI3OzB4NkK0
MDCK  MmDVSpVv[3Srb36gRZN{[Xl? M3TmT|ExKML3TR?= MXKyOEBp MmXNSG1UVw>? M1OzZpVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKFSJRj5OtlEh[W6mIFPUS2bDqA>? MVOyOlIxOjN3Mh?=
MDCK  NFTZe2FHfW6ldHnvckBCe3OjeR?= NYWzdY01OTBiwsXN M3HHVFI1KGh? NIX1XoRFVVOR Ml;5bY5pcWKrdIOgeIhmKGmwY4LlZZNm\CCneIDy[ZN{cW:wIH;mJGZPKGOjdYPl[EBjgSCWR1[t{tIy MX:yOlIxOjN3Mh?=
Spinal cords  NIHmbolHfW6ldHnvckBCe3OjeR?= M4PNVVHDqM7:TR?= M2HyXVMxKG2rbh?= NW\X[XV5e3SrbYXsZZRmeyClQV3QJIxmfmWucx?= NUXCXINHOjZzMk[5NlY>
BeWo  M3;O[2Z2dmO2aX;uJGF{e2G7 MVGyOgKBkc7:TR?= NUniZVE1OjRxNEivO|IhcA>? MkHzcIVi\HNidH:gZY4hcW6lcnXhd4UhcW5idHjlJIV5eHKnc4Ppc44hd2Zib4To[ZIh\nW|aX;uJI1iemuncoO= M4i0blI3ODV|NUS5
bovine oocytes NFXHS5VHfW6ldHnvckBCe3OjeR?= MlnrNVAxyqEQvF2= MUGxNuKhcA>? MnmzbY5pcWKrdIOgeIhmKGWoZnXjeEBw\iCQUGDBJIFv\C:xcjDOVHBEKHSxIIP0bY12dGG2ZTDy[ZN2dXC2aX;uJI9nKG2naX;zbZM> M1zJTFI3ODVzNkGx
Caco-2  M3PxNWZ2dmO2aX;uJGF{e2G7 NWDsUJNGOC5zL{GvNVAh|ryP MljsNlDDqG2rbh?= MWDpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gbY51emGlZXzseYxieiClQV3QJIxmfmWucx?= MWeyOlA1QTFyMh?=
Caco-2  M1THeWZ2dmO2aX;uJGF{e2G7 NHjmS4wxNjFxMT:xNEDPxE1? M3fk[VI1KGh? M{faUYlv[3KnYYPld{BOWlB{IIDyc5RmcW5ibHX2[Yw> MXWyOlA1QTFyMh?=
AML-12  NFfTZYNHfW6ldHnvckBCe3OjeR?= M4i1ZlIxKM7:TR?= MUOzJIg> MlTheZBz\We3bHH0[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCuZY\lcJMh[XRiVHjyMVQyOSCjbnSgV4VzNTR7Mx?= MVWyOlA1QDl6NR?=
AML-12  NIrO[FJHfW6ldHnvckBCe3OjeR?= NITJXFczOCEQvF2= MonDNU05KGh? M3zGN4lv[3KnYYPld{BodHWlb4PlJJBzd2S3Y4Tpc44> MkDsNlYxPDh7OEW=
AML-12  NXn6Z3BVTnWwY4Tpc44hSXO|YYm= MVuyNEDPxE1? M37xcVMhcA>? MWL1dE1z\We3bHH0[ZPDqFCpY{HhMOKhWGWyY3usJIFv\MLiR{\wZ:KhdVKQQTDs[ZZmdHN? Mn\FNlYxPDh7OEW=
AML-12  MXPGeY5kfGmxbjDBd5NigQ>? M3jqN|IxKM7:TR?= M1;MdlMhcA>? NFf0TppqdmS3Y3XzJJRp\SCmZYDoc5NxcG:{eXzheIlwdiCxZjDDVnREOsLi NHLsNWUzPjB2OEm4OS=>
RBMECs NF3Zb2pHfW6ldHnvckBCe3OjeR?= MVW1xsDPxE1? NHv0[WsyKGh? MornbY5pcWKrdIOgSW1CWC2LST3pcoR2[2WmIHnuZYN1cX[jdHnvckBw\iCUYYCxxsA> MnXlNlYxPDR4NkO=
EndoC-βH1 NInEOZJHfW6ldHnvckBCe3OjeR?= NGrG[Yg2yqEQvF2= NGHsXmwyKGh? NHTrfpBxd3SnboTpZZRmeyCpbIXjc5NmNWmwZIXj[YQhcW6|dXzpckB{\WO{ZYTpc44hcW5idHjlJJBz\XOnbnPlJI9nKGeudXPvd4U> M1LyOlI3ODJ6NU[y
EndoC-βH1 MoPISpVv[3Srb36gRZN{[Xl? NFXuS4Y2yqEQvF2= M4f1N|EhcA>? Mn3LcIVi\HNidH:gZUB{fHKxbnegZ2FOWCCrbnPy[YF{\Q>? MlrWNlYxOjh3NkK=
SH-SY5Y NXX4e|h[TnWwY4Tpc44hSXO|YYm= M{DYOFMxKM7:TR?= M1\CZlMxKG2rbh?= MWHEUXNQ NVvBb29{e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGGldHn2ZZRqd25ib3[gVGtC MXGyOlAzPTF|Nx?=
PC-3 M4ricGZ2dmO2aX;uJGF{e2G7 MoS4OFAhyrWP M2TwO|IhcA>? MUDEUXNQ MVvs[YFleyC2bzDQVFJCKGGldHn2ZZRqd25? NXK0PVhtOjZyMkO4N|Y>
PC-3 NWrOd2I5S2WubDDWbYFjcWyrdImgRZN{[Xl? MWK0NEDDvU1? M2fK[VI1NzR6L{eyJIg> NILnVpRFVVOR NYDnRZBz\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRqdWViZHXw[Y5l\W62bIm= M1m1bFI3ODJ|OEO2
SCG M1vJNWZ2dmO2aX;uJGF{e2G7 NGrQZ4EzOCEQvF5CpC=> M1TLOmROW09? NW\HUpNqemW4ZYLzbYJtgSC|dYDwdoV{e2W|IFnLWkB4cXSqIHGgTWM2OCCxZjCyOE41KM7:TR?= MWmyOVk3OjF|Mh?=
HEK-293 NYjEZXp3TnWwY4Tpc44hSXO|YYm= NYPlVplFOzVizszNxsA> NVzWWI5nTE2VTx?= MV\pcoR2[2W|IHGgZ49ve3CrY4XveZMh6oDeaX7hZ5RqfmG2aX;u5qCeKG:oIITo[UBMfjJwMTDjeZJz\W62 MXqyOVk3OjF|Mh?=
SCG NV;lXpA3TnWwY4Tpc44hSXO|YYm= MorONVAxKM7:TdMg NV\LO|FiTE2VTx?= NIG3XJRz\WS3Y3XzJJRp\SCneHPpeIFjcWyrdImgc4YhW0OJIH7leZJwdnN? M4LmfVI2QTZ{MUOy
PCCL3 NH7IR4ZHfW6ldHnvckBCe3OjeR?= NXXie4xGOTBiwsXN NYHRZodvOjRiaB?= NHXjZphmdmijbnPld{BFfU:6MjDwdo9ud3SncjD0doFve2O{aYD0bY9vKGGldHn2bZR6yqEkgJu= NX63RVFPOjV7NkC5OVY>
3T3-L1 preadipocytes NFnnW3NHfW6ldHnvckBCe3OjeR?= NFnMcWgyOCEQvF5CpC=> NYK2VW5jOTJiaB?= NH;sVJNqdmS3Y3XzJGNTTUJicHjvd5Bpd3K7bHH0bY9vKGGwZDDDM2VDWM7{IHX4dJJme3Orb36= M{[yNVI2QTJ6MEW4
H295R  MUDGeY5kfGmxbjDBd5NigQ>? NH\Id4YyOMLizszN MXq0POKhcA>? NHrnPJdqdmO{ZXHz[ZMhe3Sncn;p[EBu\XSjYn;sbZRmeyCrbjD0bIUh[W6mcn;n[Y4tKG2rbnXyZYxwNSCjbnSg[4x2[2:lb4L0bYNwcWRicHH0bJdigXN? MkHPNlU5Pjl3NU[=
PBMC MX3GeY5kfGmxbjDBd5NigQ>? NUXvZ3JYPTEEoN88US=> MUCyOOKhcMLi M4PDfYlvcGmkaYTzJJRp\SCrbnPy[YF{\WRic3XjdoV1cW:wIH;mJHRPTiCrbnT1Z4VlKGK7IITo[UBFWEV? NITjd4UzPTh4NkC3PS=>
GLUTag  MmnTSpVv[3Srb36gRZN{[Xl? NU\rbGRDOTEkgJpCuW0> MnW5NE8zNzRiaB?= MljPd5RqdXWuYYTld{BIVFBvMTDz[YNz\XSrb36gZ491emWjdHXkJJdqfGhiSVLNXC=> M1j6O|I2QDN{NkOx
GLUTag  MVjGeY5kfGmxbjDBd5NigQ>? NWDjNmFXOTEkgJpCuW0> NX7xSGRjPCCq M3XwS4lv[3KnYYPld{B1cGVicFPSSWIhdGW4ZXzzJJdqfGhidHjlJGlDVVh? MmrlNlU5OzJ4M{G=
BAECs MkfVSpVv[3Srb36gRZN{[Xl? MXSyOUDPxE1? M1LsTlI1KGh? M1yxbYVvcGGwY3XzJJRp\SCjY4TpeoF1cW:wIH;mJHBRSVMQsTDifUA2KM7:TTDy[ZN3\XKjdILvcEwhXDSKUzygc5IhPC2SQWC= NILPTXczPTd7OEiyOi=>
PC12 NIfse|RHfW6ldHnvckBCe3OjeR?= MmTwNlXDqM7:TR?= MofrOFghcA>? Ml\nZYN1cX[jdHXzJINCVVB? M{XYZlI2PzZ7M{C1
GH3 NIX5U5hHfW6ldHnvckBCe3OjeR?= MnG5NeKh|ryP M{PFNFYucA>? NGXUcmRifHSnboXheIV{KHSqZTDjc5Jz\WyjdHnvckBj\XS5ZXXuJHBTVCCjbnSgRo1idDFiZYjwdoV{e2mxbh?= NVfMSlRWOjV5MkewNVg>
GH3 M2LjT2Z2dmO2aX;uJGF{e2G7 MYmxxsDPxE1? Mlf1Ok1p M{GyR4lv\HWlZYOgVHJNKGGwZDDCcYFtOSxiYoX0JI5wfCCFbH;jb{whdVKQQTDlfJBz\XO|aX;u Mn7MNlU4OjdyMUi=
BeWo NGnTRXNHfW6ldHnvckBCe3OjeR?= MWWxNQKBks7:TdMg MknjO|IhcA>? NUXqdXl2TE2VTx?= M3nYXo1m\GmjdHXzJGJmX29iY3XscEBlcW[oZYLlcpRq[XSrb36= MmS3NlU4OTN2MkW=
oocytes M4DNdGZ2dmO2aX;uJGF{e2G7 MWC1JO69VQ>? NFnUfZAzPCCq NIG1foZifHSnboXheIV{KHKqLXnud5VtcW5iYXP0bY9vKG:wIH;vZ5l1\SCJVlLEJJNq\26rZnnjZY51dHoEoB?= MXeyOVcxPzh3NB?=
SC NH[3WHpHfW6ldHnvckBCe3OjeR?= NHTkUZYxNjVizszN M1S4OFI1KGh? NInYSINucW2rY3vzJJRp\SCnZn\lZ5Qhd2ZiY1HNVEBidmGub3fzJI9vKE9zIHHu[EBOSlBiZYjwdoV{e2mxbh?= MVyyOVcxPTh5NB?=
SC M{\sdWZ2dmO2aX;uJGF{e2G7 M1TMb|AvPSEQvF2= MojuO|IhcA>? NUPiVWNHcW6lcnXhd4V{KGKxdHigT5JwgC1{MDDhcoQhVzFiZYjwdoV{e2mxbjDpckBigG:wLYLlcIF1\WRiU1PzJIJ2fCCxbnz5JGtzd3hvMkFCpC=> NUDDSmhoOjV5MEW4O|Q>
UACC-647  MlLuSpVv[3Srb36gRZN{[Xl? NFzGR4ZFVVOR NH\YO5Zt\WGmczD0c{BiKHKrc3WgbY4h[0GPUDDs[ZZmdHNiKFXDOVDDqD4EoEKwMlM6yqEQvF2p MkXjNlU4ODNyMkW=
UACC-647  M2LhcWZ2dmO2aX;uJGF{e2G7 M4HmN|ExyqEQvF2= NVrZTIkxOTVibXnu M2THbmROW09? NYnMdHpScW6qaXLpeJMhTVKNIIDoc5NxcG:{eXzheIlwdg>? MonzNlU4ODNyMkW=
UACC-647  NGSx[GJHfW6ldHnvckBCe3OjeR?= NYfsRXRFOTEEoN88US=> M{LMXlE2KG2rbh?= MUfEUXNQ NHi5S2ZqdmO{ZXHz[ZMh\UWIMjDwbI9{eGixconsZZRqd25ibHX2[Yx{yqB? NH7BboIzPTdyM{CyOS=>
SH-SY5Y  MVTGeY5kfGmxbjDBd5NigQ>? NF\N[JkyOMLizszN MWOxxsBpyqB? MXTpcoNz\WG|ZYOgUHVEKGGldHn2bZR6 NGPONVAzPTV7N{SzNy=>
SH-SY5Y  NF;IUG9HfW6ldHnvckBCe3OjeR?= Mk\LNVDDqM7:TR?= M2rYR|HDqGkEoB?= MX7pcoNz\WG|ZYOgRWdEOSCvUl7BJIxmfmWu NID5RogzPTV7N{SzNy=>
hADSCs NX\Pc5drTnWwY4Tpc44hSXO|YYm= NVyz[HQ2PeLCidM1US=> M1nSSVMxKG2rbh?= M2iyPYlv[3KnYYPld{BkSU2SIHzleoVtew>? NHTLT2UzPTV7MUmwPC=>
HEK293  MonNSpVv[3Srb36gRZN{[Xl? M2PVT|XjiIoEtV2= MlXTN|AhdWmw NFHKN29qdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? NWnWUnVyOjV3OUG5NFg>
3T3-L1 MmnVSpVv[3Srb36gRZN{[Xl? M4nWdVIvPS93IN88US=> NGPCR2wzPCCqwrC= M2q4XpNq\26rZnnjZY51dHliZHXjdoVie2W|IFHUS2wheHKxdHXpckBmgHC{ZYPzbY9vKGG2IHHscEBld3OnczD0[ZN1\WR? NWHvbVdCOjV3OUC1PVc>
OCI-Ly1  MoDtSpVv[3Srb36gRZN{[Xl? MmHPOFDDqM7:TR?= NVPIOZZ5OcLiaNMg NXLCb2V1TE2VTx?= NXG1T204cW6mdXPld{B1cGViaX7jdoVu\W62IH;mJINCVVBiY3;uZ4VvfHKjdHnvcpM> MV:yOVU4PjJ{MB?=
OCI-Ly18  MmP5SpVv[3Srb36gRZN{[Xl? M3fwSFQxyqEQvF2= M1XxeFHDqGkEoB?= NHPtUoNFVVOR MomwbY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= M{HuNlI2PTd4MkKw
BeWo M3PXSWZ2dmO2aX;uJGF{e2G7 NGfpdpkzOMLiwsXN NIPVT|k1QMLiaB?= MXLEUXNQ M1mxN4lv[3KnYYPld{B1cGViZHnm[oVz\W62aXH0bY9vKG:oIFLlW48h[2WubIO= NGfPe3czPTV4Nke0NC=>
BeWo NVuwXVE4TnWwY4Tpc44hSXO|YYm= M1LqNlIxyqEEtV2= NYj2T|l{PDkEoHi= NHH2bWNFVVOR MXLpcoNz\WG|ZYOgeIhmKGGmaHXzbY9vKG:oIGTIVE0yKG2xbn;jfZRmew>? NWHwSnlvOjV3Nk[3OFA>
LNCaP  MnHESpVv[3Srb36gRZN{[Xl? MXOxNOKh|ryP NHLzO3UyOiCqwrC= MoLrSG1UVw>? M3PB[olv\HWlZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBw\iCFUlXCNUBi[3Srdnn0fS=> NELMZ|MzPTV2OEC5PS=>
ThGCs  NVrKe2xKTnWwY4Tpc44hSXO|YYm= MnjyNVDjiIsQvF2= MUe05qCLcA>? NEHkS2ZifWevZX70d{BJUUZzQTDs[ZZmdHNidHjheEB4\XKnIIP0bY12dGG2ZXSgZpkhS2:FbEK= M3vSTVI2PDN|MEK3
ThGCs  MoTCSpVv[3Srb36gRZN{[Xl? MUOxNQKBks7:TR?= M3O2WVTjiIqq MWDpcoNz\WG|ZYOgR49EdDJvaX7keYNm\CCHRF6yxsBo\W6nIHX4dJJme3Orb36= NXLkR49jOjV2M{OwNlc>
ThGCs  M3zpNGZ2dmO2aX;uJGF{e2G7 MVGxNQKBks7:TR?= NEHRR2k{KGh? MVvpcohq[mm2czD0bIUh\W[oZXP0JI9nKEh{T{Kgc44hTUSQMjDtVm5C M{\ETVI2PDN|MEK3
RBMECs MkDnSpVv[3Srb36gRZN{[Xl? M2S4U|AvODVxMD61M|Uh|ryP MlHZNE4zPSCq NXPtUXFPcW6lcnXhd4V{KGODTWCgZ49v[2WwdILheIlwdg>? NHrNUpczPTRzNk[1NS=>
RBMECs MojISpVv[3Srb36gRZN{[Xl? M4m1e|XDqM7:TR?= MYqxJIg> M3\LZoJtd2OtczD0bIUh[WO2aY\heIlwdiCxZjDSbI9CN1KRQ1ugbY5lfWOnZDDifUBGVUGSLVnJ MlrsNlU1OTZ4NUG=
RBMECs MWPGeY5kfGmxbjDBd5NigQ>? NUeyTVlQPcLizszN M3vwOFEhcA>? M{PibJBz\X[nboTzJJRp\SCHTVHQMWlKNWmwZIXj[YQhXEWHUjD2ZYx2\SCmZXPy[YF{\Q>? MXiyOVQyPjZ3MR?=
RBMECs NE\SfnRHfW6ldHnvckBCe3OjeR?= NETmd4U2yqEQvF2= NXfiXnZLOSCq M1fudZBz\X[nboTzJJRp\SCrbnPy[YF{\SCrbjDIVnAh\my3eDDhZ5Jwe3NidHjlJGJVSiCrbnT1Z4VlKGK7IDDFUWFRNUmL MoLLNlU1OTZ4NUG=
RBMECs NFv4W4NHfW6ldHnvckBCe3OjeR?= M2fFNlXDqM7:TR?= NUXG[odMOSCq NGDwS3hqdmirYnn0d{B1cGViZHXjdoVie2WmIH;mJIFud3WwdDDv[kBbVy1zIHnuJG1HeyCrbnT1Z4VlKGK7IFXNRXAuUUl? NHLIbHQzPTRzNk[1NS=>
RBMECs M4jUZ2Z2dmO2aX;uJGF{e2G7 M2fE[lXDqM7:TR?= NGSzUGYyKGh? Mli5doV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iWl:tNUBlcXO2cnnieZRqd25ic3XlckB4cXSqIFXNRXAuUUlidILlZZRu\W62 NXzoVXhZOjV2MU[2OVE>
RBMECs MWPGeY5kfGmxbjDBd5NigQ>? MWS1xsDPxE1? M3fnSFEhcA>? NHvuO3JjdG:la4OgeIhmKEWPQWCtTWkucW6mdXPl[EBkcGGwZ3WgbY4hVUyFIIDoc5NxcG:{eXzheIlwdg>? MlvnNlU1OTZ4NUG=
RBMECs NFq3dZhHfW6ldHnvckBCe3OjeR?= NEjJT3Q2yqEQvF2= NHL0cHQyKGh? NFjUWJZjdG:la4OgeIhmKGGldHnuJIN6fG:|a3Xs[ZRwdiC{ZXHydoFv\2WvZX70JJNm\W5id3n0bEBGVUGSLVnJJJRz\WG2bXXueOKh Mo\1NlU1OTZ4NUG=
Primary bovine chondrocytes NH7xbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HMPVXPxE1? NXHU[ZNsPDhiaB?= M2HJWZJmfmW{c3XzJJRp\SCrbnjpZol1d3K7IHXm[oVkfCCxZjDj[Yxm[2:6aXKgc44heHKxbHnm[ZJifGmxbjDpckBoem:5dHigdIxifGViY3jvcoRzd2O7dHXz NYrwS|A5OjV2ME[wNVY>
EM1  Mlv3SpVv[3Srb36gRZN{[Xl? Mkj0NVXjiIsQvF2= MVm0PEBp NHfzfGdz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBNUUcEoH;yxsBRXEeVMtMgbY7DqEODTGKtJI9zyqCHUFHDNk1{cWynbnPl[EBGVTFiY3XscJPDqA>? M{LYelI2Ozd6Nk[x
BeWo  MVfGeY5kfGmxbjDBd5NigQ>? NXf1XHpEOjEEoNM1US=> MkS0OFjDqGkEoB?= M1TkTmROW00EoB?= NX2yWVU4cW6lcnXhd4V{KHSqZTDi[ZRiNWiFRzDy[Yxm[XOn NHjBem8zPTN4MkK2NC=>
BeWo  NYnk[IgxTnWwY4Tpc44hSXO|YYm= MUWyNOKhyrWP Mo[5OFjDqGkEoB?= NXOzTGlWTE2VT9Mg NXTkU3Yz\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXygc4YhXE2HTV[xOi=> Mn;UNlU{PjJ{NkC=
BeWo  NHvqSGlHfW6ldHnvckBCe3OjeR?= NH20cJUzOMLiwsXN MVS0POKhcMLi MUHEUXNQyqB? MlTH[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gS2NONTF? MUKyOVM3OjJ4MB?=
granulosa cells M1rKRmZ2dmO2aX;uJGF{e2G7 NYr5S|hHOTBizszN NIT1e3kyOi9{NDDo NF\1emFqdmO{ZXHz[ZMhfGinIHzleoVteyCxZtMgVmdUOsLibWLORS=> NVP0Z3E5OjV|M{mxNFU>
granulosa cells Mk\pSpVv[3Srb36gRZN{[Xl? MX[xNEDPxE1? MkSwNVIwOjRiaB?= MUPpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC{ZYDvdpRmeiCjY4Tpeol1gSCob4KgeIhmKGyxbnfld5Qh\nKjZ33lcpQhMOLKkki1OE8sOTiUR2OyMmxWSyl? NWPtcW5GOjV|M{mxNFU>
granulosa cells NVzsUphVTnWwY4Tpc44hSXO|YYm= NHKzXpAyOCEQvF2= MX[yOEBp MoWzbY5kemWjc3XzJJRp\SCrboTlcpNqfHlib3[gSG5CN3C{b4TlbY4h[2:vcHzlfC=> NGnqPGMzPTN|OUGwOS=>
granulosa cells MVrGeY5kfGmxbjDBd5NigQ>? MY[xNEDPxE1? MoXPNlQhcA>? MYnpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCUR2OyJJBzd22xdHXyJIFkfGm4aYT5 MUGyOVM{QTFyNR?=
SK-N-AS  NWT3W|lXS2WubDDWbYFjcWyrdImgRZN{[Xl? MoPGNVAh|ryPwrC= NYnQSmo1OjRxNEigbC=> NIfZZnZmdmijbnPld{B1cW2nLXTldIVv\GWwdHz5JINmdGy3bHHyJJZq[WKrbHn0feKh MV2yOVI3PjB4Mx?=
SK-N-AS  NF74eZNHfW6ldHnvckBCe3OjeR?= MWKxNEDPxE4EoB?= M3f3VlI1KGh? Mn;QbY5kemWjc3XzJJRp\SClQV3QJIxmfmWuc9Mg MlLNNlUzPjZyNkO=
SK-N-AS  NXvKc2xGTnWwY4Tpc44hSXO|YYm= M3vyWlExKM7:TdMg M3v2W|I1KGh? NX\YWJc2cW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGO7Y3zpckBFOQ>? MWCyOVI3PjB4Mx?=
SK-N-AS  NV;r[m94TnWwY4Tpc44hSXO|YYm= NWn4boFpOTBizszNxsA> M1jjeVMxKG2rbh?= MnP5bY5lfWOnczDwbI9{eGixconsZZRqd25ib3[g{tIu[2G2ZX7pckApe2W{Nke1LUwheC2JU1uz{tIhMHOnckmpJIFv\CClb37jc41qfGGwdDDobYdp\XJibHX2[Yx{KG:oIHHjeIl3\SxidX7wbI9{eGixconsZZRm\CxizsKtZ4F1\W6rbh?= MoP3NlUzPjZyNkO=
SK-N-AS  M1jwfmZ2dmO2aX;uJGF{e2G7 MVOxNEDPxE4EoB?= MnmwNVAwOzBxNkCgcYlv Mlz1bY5kemWjc3XzJIxmfmWuczDv[kBxNc7{LXPheIVvcW5iKIPldlY4PSliYX7kJIlv\HWlZYOgZYNkfW23bHH0bY9vKG:oIICt{tIu[2G2ZX7pckApe2W{Nke1LUBqdiBqcHXybUlvfWOuZXHyJJJm\2mxboO= M3m2O|I2OjZ4ME[z
SK-N-SH M4e5U2NmdGxiVnnhZoltcXS7IFHzd4F6 MUGxNEDPxE4EoB?= NYrMWW5xPDhiaB?= MoLC[Y5p[W6lZYOgV2suVi2VSDDu[ZVzd2KuYYP0c41iKGOnbHygeoli[mmuaYT5 Mo\RNlUzPjZyNkO=
HEK‐CFTR NHPGdI9HfW6ldHnvckBCe3OjeR?= M4CwPVLjiJN3MNMg{txO MnHZNE0yOiCvaX6= MYjEUXNQyqB? NHrxRXFqdmS3Y3XzJIEh\G:|ZfMAlIRmeGWwZHXueEBqd2SrZHWg[YZndHW6wrC= NVThWplDOjV{NkOyNFc>
L6 M{exVWZ2dmO2aX;uJGF{e2G7 MUS0NEDDvU1? NUjHWFR[OjRiaB?= NUnKepl[cW6qaXLpeJMhTE2KMT3pcoR2[2WmIFHreEBi[3SrdnH0bY9v NHewZ4gzPTJ2N{W1NC=>
MIN6  NEnFOFFHfW6ldHnvckBCe3OjeR?= NX\ZdZd7OTBizszNxsA> NIHIZZY{KGh? M160[olv[3KnYYPld{BFOyCvUl7BJIV5eHKnc4Ppc44> NFjZfoMzPTJ2MUGyOC=>
ventricular cardiomyocytes  NVviWnBOTnWwY4Tpc44hSXO|YYm= MlHoNE4xOS1zMDFOwG0> M1H4Uolv[3KnYYPld{Ah[0GPUDDhZ4N2dXWuYYTpc44> NUTMU4t2OjV{MEOxNVM>
ventricular cardiomyocytes  NED3XYhHfW6ldHnvckBCe3OjeR?= NYfm[o51OC5yMT2xNEDPxE1? NUTQXZVb\X[xa3XzJIFvKGmwb4Tyc5Bq[yC{ZYPwc45{\SBzMkFCtVE2LSCjYn;2[UBj[XOjbDD3bZRpKGGwIFXDOVDDqG:oIEKuNkDDvU1? NFLLepUzPTJyM{GxNy=>
BeWo  MXTGeY5kfGmxbjDBd5NigQ>? NV7JcIVqOjBiwsXN MW[0PEBp NGDkVWxFVVORwrC= M4H6XYlv\HWlZYOgZ4VtdCCodYPpc44> NF23dIMzPTF6NES3Oy=>
THP-1  NIPiT5dHfW6ldHnvckBCe3OjeR?= NIrPZVUyNzFyIN88US=> NVTHbGFsOsLiaB?= NH:zVodFVVORwrC= NUnkV5ZKe3WycILld5NmeyCPQ2CtNUBxem:mdXP0bY9vyqB? MV6yOVE2PDh6Mh?=
Huh-7 NEnM[XNHfW6ldHnvckBCe3OjeR?= NWfwSYRQOC1{MDFOwG0> NUm5clF5OiCqwrC= NWXSXIQ1emW|dXz0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KGmwY4LlZZNmKGmwIHOtUZlkKGW6cILld5Nqd25iYYSgeIhmKHC{b4TlbY4h[W6mIH3SUmEhdGW4ZXzz NWD1SoNZOjVzMEm4N|Q>
C6 NWnUV4dzTnWwY4Tpc44hSXO|YYm= MX:xNEDPxE4EoB?= NIO2fVYzOCCvaX6= NIDvc|JqdmO{ZXHz[ZMh[0GPUDDhZ4N2dXWuYYTpc44> NHfPWGEzPTB4OUSxOy=>
SW480 NV\kPWNSTnWwY4Tpc44hSXO|YYm= M3;VSVQxyqEQvF2= MXK0POKhcA>? M1Ly[GROW09? NY\2T5k4[WO2aY\heIV{KFCSMlG= MX[yOFk6PzR3MR?=
HT-29  MnvWSpVv[3Srb36gRZN{[Xl? NGHhbIo1OMLizszN NH\nSGw1QMLiaB?= M{nxbmROW09? Ml\ZZYN1cX[jdHXzJHBROkF? NF;UUYQzPDl7N{S1NS=>
SW480 M2jMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfiOGc1OMLizszN MnfkNE04OiCq M2D5TWROW09? NYjQWWhIcW6qaXLpeJMh[2WubDDndo94fGhidHnt[UBl\XCnbnTlcpRtgQ>? M1jpU|I1QTl5NEWx
HT-29  MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nDVlQxyqEQvF2= NXTYdXlUOC15MjDo M{XNdWROW09? MV7pcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 MViyOFk6PzR3MR?=
SW480 NHrnVXlHfW6ldHnvckBCe3OjeR?= MlXFOFDDqM7:TR?= MnTtO{Bl NXvtd4pbTE2VTx?= MofmdoVlfWOnczDjc4xwdm:|cHjldoUh\m:{bXH0bY9vKGOjcHHibYxqfHoEoB?= NWrzNWpvOjR7OUe0OVE>
HT-29  NELsZnhHfW6ldHnvckBCe3OjeR?= M3;3RlQxyqEQvF2= Mlz6O{Bl MmTVSG1UVw>? NUO1U|RLemWmdXPld{Bkd2yxbn;zdIhmemViZn;ycYF1cW:wIHPhdIFjcWyrdIpCpC=> NFzxdYIzPDl7N{S1NS=>
SW480 M{fKfWFxd3C2b4Ppd{BCe3OjeR?= NGLlSm81OMLizszN MX60POKhcA>? NYG3dG82TE2VTx?= NHmzN45qdmS3Y3XzJIFvKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZTCzM|c> NV6yT4JqOjR7OUe0OVE>
HT-29  MV;BdI9xfG:|aYOgRZN{[Xl? M2G3XFQxyqEQvF2= NFz4bHA1QMLiaB?= MXrEUXNQ MYLpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= M3vDOFI1QTl5NEWx
SW480 NYKwNpd6SXCxcITvd4l{KEG|c3H5 NW\2blBRPDEEoN88US=> MlnyOFjDqGh? NEHQ[GxFVVOR M3;qO4lv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= NH:wRWIzPDl7N{S1NS=>
HT-29  MlT5RZBweHSxc3nzJGF{e2G7 NFy4XJk1OMLizszN Mmq0OFjDqGh? NX;tW|hPTE2VTx?= MUTpcoR2[2W|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS| M{XKZlI1QTl5NEWx

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

Protocol

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.5
Formula

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
Synonyms Coleonol

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

cAMP Signaling Pathway Map

Tags: buy Forskolin | Forskolin supplier | purchase Forskolin | Forskolin cost | Forskolin manufacturer | order Forskolin | Forskolin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID